Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
First Claim
Patent Images
1. A method of screening to identify a candidate agent that agonizes interaction of a regulator of G protein signaling (RGS) polypeptide and a G protein subunit alpha q (Gα
- q) polypeptide, said method comprising;
(a) contacting a RGS polypeptide and a Gα
q polypeptide with a candidate agent, wherein said RGS polypeptide comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of human RGS2 (SEQ ID NO.;
26), human RGS6 (SEQ ID NO.;
27), human RGS7 (SEQ ID NO.;
7), human RGS9 (SEQ ID NO.;
11), or human RGS11 (SEQ ID NO.;
9), and, wherein said Gα
q polypeptide comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of human Gα
q (SEQ ID NO.;
13);
(b) detecting an amount of binding of said RGS polypeptide to said Gα
q polypeptide in the presence of the candidate agent;
(c) detecting a reference amount of binding of said RGS polypeptide to said Gα
q polypeptide in the absence of the candidate agent; and
(d) comparing the amount of binding of said RGS polypeptide to said Gα
q polypeptide in the presence of the candidate agent to the reference amount of binding,wherein an increase in the amount of binding detected in the presence of the candidate agent relative to the reference amount of binding indicates that the candidate agent binds to said RGS polypeptide or Gα
q polypeptide, and agonizes interaction of RGS and Gα
q, and wherein said candidate agent is not a guanine nucleotide.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods that are useful for the treatment or prevention of smooth muscle disorders such as urinary incontinence and compounds that are useful in such methods.
10 Citations
6 Claims
-
1. A method of screening to identify a candidate agent that agonizes interaction of a regulator of G protein signaling (RGS) polypeptide and a G protein subunit alpha q (Gα
- q) polypeptide, said method comprising;
(a) contacting a RGS polypeptide and a Gα
q polypeptide with a candidate agent, wherein said RGS polypeptide comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of human RGS2 (SEQ ID NO.;
26), human RGS6 (SEQ ID NO.;
27), human RGS7 (SEQ ID NO.;
7), human RGS9 (SEQ ID NO.;
11), or human RGS11 (SEQ ID NO.;
9), and, wherein said Gα
q polypeptide comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of human Gα
q (SEQ ID NO.;
13);(b) detecting an amount of binding of said RGS polypeptide to said Gα
q polypeptide in the presence of the candidate agent;(c) detecting a reference amount of binding of said RGS polypeptide to said Gα
q polypeptide in the absence of the candidate agent; and(d) comparing the amount of binding of said RGS polypeptide to said Gα
q polypeptide in the presence of the candidate agent to the reference amount of binding,wherein an increase in the amount of binding detected in the presence of the candidate agent relative to the reference amount of binding indicates that the candidate agent binds to said RGS polypeptide or Gα
q polypeptide, and agonizes interaction of RGS and Gα
q, and wherein said candidate agent is not a guanine nucleotide.- View Dependent Claims (2, 3, 4, 5)
- q) polypeptide, said method comprising;
-
6. A method for identifying an agent that modulates urinary incontinence, said method comprising:
-
(a) contacting a RGS polypeptide and a Gα
q polypeptide with a candidate agent, wherein said RGS polypeptide comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of human RGS2 (SEQ ID NO.;
26), human RGS6 (SEQ ID NO.;
27), human RGS7 (SEQ ID NO.;
7), human RGS9 (SEQ ID NO.;
11), or human RGS11 (SEQ ID NO.;
9), and wherein said Gα
q polypeptide comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of human Gα
q (SEQ ID NO.;
13);(b) detecting an amount of binding of said RGS polypeptide to said Gα
q polypeptide in the presence of the candidate agent;(c) detecting a reference amount of binding of said RGS polypeptide to said Gα
q polypeptide in the absence of the candidate agent;(d) comparing the amount of binding of said RGS polypeptide to said Gα
q polypeptide in the presence of the candidate agent to the reference amount of binding,wherein an increase in the amount of binding detected in the presence of the candidate agent relative to the reference amount of binding indicates that the candidate agent binds to said RGS polypeptide or α
q polypeptide, and agonizes interaction of RGS and Gα
q; and(e) testing if the candidate agent that agonizes interaction of RGS and Gα
q modulates urinary incontinence, and wherein said candidate agent is not a guanine nucleotide.
-
Specification